BAR­DA slows its $9B en­gine for new Covid-19 ther­a­peu­tics

The Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­i­ty is cool­ing its jets in look­ing for new, po­ten­tial Covid-19 treat­ments, at least in the near term.

An HHS spokesper­son told End­points News via email, “to date, BAR­DA has ob­lig­at­ed more than $9 bil­lion for the de­vel­op­ment and/or pur­chase of 13 ther­a­peu­tics, be­gin­ning in Feb­ru­ary 2020 with sup­port to de­vel­op Re­gen­eron’s mon­o­clon­al an­ti­body ther­a­peu­tic. Ther­a­peu­tics are an im­por­tant el­e­ment of the COVID-19 re­sponse, and we are fo­cused on the pro­grams cur­rent­ly un­der­way and/or in ne­go­ti­a­tion us­ing the funds avail­able to us.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER